title: Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.
authors.affiliation: From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece thanasisfountas@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Fountas
authors.affiliation: From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.
authors.forename: S
authors.initials: S
authors.lastname: Tigas
authors.affiliation: From the Department of Endocrinology, University Hospital of Ioannina, Ioannina, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Tsatsoulis
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D000069448:Denosumab; D006801:Humans; D006934:Hypercalcemia; D010257:Paraneoplastic Syndromes; D010281:Parathyroid Hormone; D010282:Parathyroid Neoplasms
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D010281:Parathyroid Hormone; D000069448:Denosumab